EVP, Interim CFO of Valeant Pharmaceuticals International (VRX) Philip Walden Jr Loberg buys 7,500 shares of VRX on 06/09/2011 at an average price of $52.82 a share.

Valeant Pharmaceuticals International has a market cap of $15.75 billion; its shares were traded at around $52.83 with a P/E ratio of 50.31 and P/S ratio of 13.33.

Directors and Officers Recent Trades:

Buy: EVP, GC & Corp. Sec. Robert Roswell Chai-onn bought 10,000 shares of VRX stock on 05/27/2011 at the average price of 50.76. Robert Roswell Chai-onn owns at least 167,774 shares after this. The price of the stock has increased by 4.08% since.

Buy: Director Norma Ann Provencio bought 2,000 shares of VRX stock on 05/16/2011 at the average price of 50.55. Norma Ann Provencio owns at least 155,007 shares after this. The price of the stock has increased by 4.51% since.

Buy: Director Katharine Berghuis Stevenson bought 2,000 shares of VRX stock on 03/14/2011 at the average price of 40.59. Katharine Berghuis Stevenson owns at least 5,000 shares after this. The price of the stock has increased by 30.16% since.

Buy: Director Norma Ann Provencio bought 1,575 shares of VRX stock on 03/04/2011 at the average price of 39.87. Norma Ann Provencio owns at least 117,979 shares after this. The price of the stock has increased by 32.51% since.

Sell:ValueAct+Holdings%2C+L.P.">Holdings, L.p. Valueact sold 4,498,180 shares of VRX stock on 05/13/2011 at the average price of 49.99. Holdings, L.p. Valueact owns at least 15,095,302 shares after this. The price of the stock has increased by 5.68% since.

Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC.
Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.